 The primary objective of the trial is to evaluate the efficacy of HORIZANT 300 mg and 600 mg, compared to placebo, at 12 weeks of treatment, for the treatment of Restless Legs Syndrome RLS in adolescents 13 to 17 years of age diagnosed with moderate-to-severe primary RLS. 